The importance of Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Programs (ADAPs) in federal, state, and local initiatives to end the HIV epidemic in the United States cannot be overstated. For more than 35 years ADAPs have played a central role in ensuring equitable access to antiretrovirals and other medicines essential to not only health and survival, but also the prevention of HIV transmission.
NASTAD’s National RWHAP Part B ADAP Monitoring Project Annual Report documents key trends, challenges, and successes faced by ADAPs ensuring access to prescription drugs for people living with HIV/AIDS (PLWHA) nationally. Following a comprehensive Monitoring Project utilization, needs, and participation assessment conducted in 2021and 2022 with input from RWHAP Part B and ADAP staff, federal partners, and community stakeholders, NASTAD is returning the focus of the Annual Report to ADAPs with less emphasis on RWHAP Part B more broadly. The 2023 Annual Report includes longitudinal data spanning several domains widely considered vital to the success of ADAPs and, importantly, the identification of opportunities to ensure the best possible health outcomes for low-income PLWHA who would otherwise have limited or no prescription drug coverage.
Unless otherwise noted, findings highlighted in this report are based on budgetary data for fiscal year 2021 and programmatic data for calendar year 2021 received from 45 states, the District of Columbia, and one U.S. territory (Puerto Rico). No fiscal or programmatic data were received from Alabama, Maryland, Mississippi, Virginia, West Virginia, the U.S. Virgin Islands, or the Pacific Island Jurisdictions.